BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 1857987)

  • 1. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides.
    Szczylik C; Skorski T; Nicolaides NC; Manzella L; Malaguarnera L; Venturelli D; Gewirtz AM; Calabretta B
    Science; 1991 Aug; 253(5019):562-5. PubMed ID: 1857987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
    Skórski T; Szczylik C; Malaguarnera L; Calabretta B
    Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Zon G; Iozzo RV; Calabretta B
    Blood; 1996 Aug; 88(3):1005-12. PubMed ID: 8704208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
    Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides.
    Ratajczak MZ; Hijiya N; Catani L; DeRiel K; Luger SM; McGlave P; Gewirtz AM
    Blood; 1992 Apr; 79(8):1956-61. PubMed ID: 1562723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides.
    Szczylik C; Skórski T; Malaguarnera L; Hetman J; Chen ST; Calabretta B
    Folia Histochem Cytobiol; 1996; 34(3-4):129-34. PubMed ID: 8967957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides.
    de Fabritiis P; Amadori S; Calabretta B; Mandelli F
    Bone Marrow Transplant; 1993 Sep; 12(3):261-5. PubMed ID: 8241986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells.
    Skorski T; Kanakaraj P; Nieborowska-Skorska M; Ratajczak MZ; Wen SC; Zon G; Gewirtz AM; Perussia B; Calabretta B
    Blood; 1995 Jul; 86(2):726-36. PubMed ID: 7606002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells.
    de Fabritiis P; Skorski T; De Propris MS; Paggi MG; Nieborowska-Skorska M; Lisci A; Buffolino S; Campbell K; Geiser T; Calabretta B
    Leukemia; 1997 Jun; 11(6):811-9. PubMed ID: 9177433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
    Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific antisense oligomer anti Bcr-abl junctions in chronic myeloid leukemia: a cell cycle analysis and CFU-GM study.
    Mahon FX; Belloc F; Vianes I; Barbot C; Boiron JM; Cowen D; Lacombe F; Brizard A; Bilhou-Nabera C; Bernard P
    Leuk Lymphoma; 1995 Nov; 19(5-6):423-9. PubMed ID: 8590842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma.
    Bellucci R; Sala R; De Propris MS; Cordone I; de Fabritiis P
    Leuk Lymphoma; 1999 Nov; 35(5-6):471-81. PubMed ID: 10609784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.
    Gewirtz AM
    Leuk Lymphoma; 1993; 11 Suppl 1():131-7. PubMed ID: 7504543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
    Skorski T; Nieborowska-Skorska M; Nicolaides NC; Szczylik C; Iversen P; Iozzo RV; Zon G; Calabretta B
    Proc Natl Acad Sci U S A; 1994 May; 91(10):4504-8. PubMed ID: 8183938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-2 inhibits proliferation of K562 cells and reduces accumulation of bcr/abl mRNA and oncoprotein.
    Dilloo D; Hanenberg H; Lion T; Burdach S
    Leukemia; 1995 Mar; 9(3):419-24. PubMed ID: 7885040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
    J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of bcr/abl gene in single hemopoietic progenitors in some patients with chronic myelogenous leukemia.
    Misawa M; Maeda H; Hara H; Yamamoto Y; Furuyama J
    Stem Cells; 1993 Nov; 11(6):536-42. PubMed ID: 7509222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide.
    Skorski T; Nieborowska-Skorska M; Barletta C; Malaguarnera L; Szcyzlik C; Chen ST; Lange B; Calabretta B
    J Clin Invest; 1993 Jul; 92(1):194-202. PubMed ID: 8325984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
    Smetsers TF; Skorski T; van de Locht LT; Wessels HM; Pennings AH; de Witte T; Calabretta B; Mensink EJ
    Leukemia; 1994 Jan; 8(1):129-40. PubMed ID: 8289478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors.
    Bhatia R; Verfaillie CM
    Blood; 1998 May; 91(9):3414-22. PubMed ID: 9558400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.